PUBLICATIONS (Based on Research Carried Out at Vilab II)

 

 

GENERAL VIROLOGY  

 

Prince AM, Brotman B, Richard L, White T, Pollack N, Riddle J.  Incidence of hepatitis A virus (HAV) infection in rural Liberia. J Med Virol 15: 421-428, 1985. [205]

   

Williams B, Prince AM, Huima T, Brotman B.  Spuma viruses isolated from sources containing agents of non-A, non-B hepatitis (NANB) do not cause NANB hepatitis. J Med Virol 24: 263-274, 1988. [229]

   

Marx PA, Yen L, Lerche NW, Sutjipto S, Gettie A, Yee JA, Brotman BH, Prince AM, Hanson A, Webster RG, Desrosiers RC.  Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a West African sooty mangabey. J Virol 65(8): 4480-4485, 1991. [266]      

 

HEPATITIS B VIRUS  

 

Prince AM.  Hepatitis associated antigen: Long term persistence in chimpanzees. In ÒMedical PrimatologyÓ (1970) Basel: Karger, pp. 731, 1971. [38]

   

Prince AM.  Immunologic distinction between I.H. and S.H.  Editorial. N Engl J Med 281: 163-164, 1969. [41]

 

Prince AM, Hargrove RL, Szmuness W, Cherubin CE, Fontana VJ, Jefferies GH.  Immunologic distinction between infectious and serum hepatitis. N Engl J Med 282: 987-991, 1970. [42]

 

 

Vnek J, Prince AM, Hashimoto N, Ikram H.  Association of normal serum protein antigens with chimpanzee hepatitis B surface antigen particles. J Med Virol 2:319-333, 1978. [137]

   

Krawczynski K, Prince AM, Nowoslawski A.  Immunopathologic aspects of the HBsAg carrier state in chimpanzees. J Med Primatol 8:222-232, 1979. [150]

 

Prince AM, White T, Pollock N, Riddle J, Brotman B, Richardson L.  The epidemiology of hepatitis B infections in Liberian infants. Infection and Immunity, May 32:675-680, 1981. [156]

   

Stephan W, Prince AM, Brotman B.  Modulation of hepatitis B infection by intravenous application of an immunoglobulin preparation that contains antibodies to hepatitis B and core antigens but not to hepatitis B surface antigen. J Virol 51:420-424, 1984. [189]

 

Brotman B, Prince AM.  Occurrence of Ausab test positivity unrelated to prior exposure to hepatitis B virus. J Infect Dis 50:714-720, 1984. [192]  


Berthelot P, Courouce AM, Eyquem A, Feldmann G, Jacob J, Ravisse P, Vacher B, Moor-Jankowski J, Muchmore E, Prince AM.  Hepatitis B vaccine safety monitoring in the chimpanzee: Interpretation of results. J Med Primatol 13:119-133, 1984. [194]

 

Neurath AR, Kent SBH, Parker K, Prince AM, Strick N, Brotman B, Sproul P.  Antibodies to a synthetic peptide form the PreS 120-145 region of the hepatitis B virus envelope are virus-neutralizing. Vaccine 4:35-37, 1986. [214]

   

Takahashi K, Brotman B, Usuda S, Mishiro S, Prince AM.  Full-genome sequence analyses of hepatitis B virus (HBV) strains recovered from chimpanzees infected in the wild: implications for an origin of HBV. Virology 267: 58-64, 1999. [335]

 

Prince AM, Lee D-H, Brotman B.  Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 41: 329-332, 2001. [340]
 

Pancholi P, Lee D-H, Liu Q, Tackney C, Taylor P, Perkus M, Andrus L, Brotman B, Prince AM.  Immunotherapy of chronic hepatitis B virus infection.  Proceedings of the 10th International Symposium on Viral Hepatitis and Liver Disease, International Medical Press Ltd., Atlanta, GA, pp. 196-199, 2002. [349]

 

Ganem D, Prince AM.  Hepatitis B virus infection --- natural history and clinical consequences.  NEJM 350(11):1118-1129, 2004. [354]

 

HEPATITIS B VACCINE

 

Prince AM, Vnek J.  A new candidate hepatitis B vaccine containing sub particulate HBsAg and HBeAg. In Touraine J.L. et al., (Eds.): ÒTransplantation and Clinical Immunology,Ó Amsterdam: Excerpta Medical 10:90-97, 1979. [142]

 

Prince AM, Vnek J.  A new candidate hepatitis B vaccine containing sub particulate HBsAg and HBeAg. In E.S. Ketiladze (Eds.): ÒViral Hepatitis A and B.  Collection of Papers,Ó Moscow: The D.I. [143]

   

Prince AM, Brotman B, van den Ende MC.  Evaluation of safety and efficacy of bivalent NIH vaccine in chimpanzees. Proceedings of the International Workshop on Hepatitis B Vaccine, Paris, December 1980. Amsterdam: Elsevier/North-Holland Biomedical Press. [158]

   

Prince AM, Vnek J, Stephan W.  A new hepatitis B vaccine containing HBeAg in addition to HBsAg. Devel Biol Stand 54:13-22, 1983. [175]

 

Vnek J, Hashimoto N, Prince AM.  Immunogenicity of HBeAg in New York Blood Center Hepatitis B vaccine. Devel Biol Stand 54:217-221, 1983. [176]

 

Kaufmann R, Mondorf AW, Uthemann H, Bauer H, Prince AM.  Hepatitis B vaccine: Safety and efficacy clinical trial. Devel Biol Stand 54:223-228, 1983. [177]

 

Kaufmann R, Mondorf AW, Uthemann H, Bauer H, Prince AM.  Hepatitis B vaccine: Safety study in anti-HBs seronegative human volunteers. Devel Biol Stand 54:229-235, 1983. [178]

 

Prince AM, Brotman B, Purcell RH, Gerin JL.  Infection with hepatitis B virus after successful immunization with hepatitis B virus vaccine:  A final report on safety and immunogenicity of a bivalent aqueous subunit vaccine.  J Med Virol 15:399-419, 1985. [196]

 

Prince AM, Vnek J, Brotman B.  An affordable multideterminant plasma derived hepatitis B virus vaccine. Proc. Symposium on Virus-Associated Cancers in Africa, Nairobi, IARC Scientific Publications No. 63:355-372, 1984. [200]  


Lelie PN, Reesink HW, Niessen J, Brotman B, Prince AM.  Inactivation of 1015 chimpanzee-infectious doses of hepatitis B virus during preparation of a heat-inactivated hepatitis B vaccine. J Med Virol 23:289-295, 1987. [232]

 

Shata MT, Brotman B, Perkus M, Lee D-H, Li L, Tricoche N, Murthy K, Prince AM.  Attempted therapeutic immunization in a chimpanzee (Pan troglodytes) chronic HBV carrier with a high viral load.  J Med Primatol. 35:165-171, 2006

 

VIRUS-FREE BLOOD DERIVATIVES

 

Stephan W, Prince AM, Brotman B, van den Ende MC. Wirksamkeitsnachweis der sterilisation humaner gerinnungsfaktoren mit β-propiolactone und UV-bestrahlung. In Deutsch, E, Lechner K. (Eds.): ÒFibrinolyse, Thrombose, HŠmostase,Ó Schattauer Verlag Stuttgart, pp. 589-592, 1980. [152]

 

Stephan W, Prince AM.  Efficacy of combined treatment of factor IX-complex (PPSB) with β-propiolactone (β-PL) and ultraviolet (UV) irradiation. Protides of Biological Fluids. 28:229-232, 1980. [153]

 

Prince AM, Stephan W, Brotman B, van den Ende MC.  Evaluation of the effect of beta-propiolactone/ultraviolet irradiation (β-PL/UV) treatment of source plasma on hepatitis transmission by factor IX complex in chimpanzees.  Thrombosis and Haemostasis 44:138-142, 1980. [155]

 

Prince AM, Stephan W.  Effect of combined β-propiolactone/ultraviolet irradiation treatment on hepatitis B virus. Letter to the Editor, Lancet ii: 917, 1980. [157]

 

Stephan W, Berthold H, Prince AM.  Effect of combined treatment of serum containing hepatitis B virus with beta-propiolactone and ultraviolet irradiation. Vox Sang 41:134-138, 1981. [161]

 

Stephan W, Kotitschke R, Prince AM, Brotman B.  Long-term tolerance and recovery of β-propiolactone/ultraviolet (βPL/UV) treated PPSB in chimpanzees. Thrombosis and Haemostasis 46:511-514, 1981. [162]

 

Prince AM, Stephan W, Brotman B.  Efficacy of combined treatment of human plasma with β-propiolactone and UV irradiation. Blutkomponenten und Plasmaersatzmittel. J.R. Kalden and U.D. Koenig (Eds.) Springer-Verlag, Berlin, Heidelberg, New York, 1982, pp. 68-86. [172]

 

Kotitschke R, Stephan W, Prince AM.  Thrombogenitatstestergebnisse von kalsterilisiertem PPSB am Schimpansen. Blutkomponenten und Plasmaersatzmittle. J.R. Kalden and U.D. Koenig (eds.), Springer-Verlag, Berlin, Heidelberg, New York, 1982, pp. 107-112. [173]

 

Prince AM, Horowitz B, Brotman B, Huima T, Richardson L, van den Ende MC.  Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang 46:36-43, 1984. [185]  


Prince AM, Stephan W, Brotman B.  Inactivation of non-A, non-B virus infectivity by a beta-propiolactone/ultraviolet irradiation treatment and aerosil adsorption procedure used for preparation of a stabilized human serum. Vox Sang 46:80-85, 1984. [186]

 

Prince AM, Stephan W, Kotitschke R, Brotman B.  Inactivation of hepatitis and non-A, non-B viruses by combined use of Tween 80, β-propiolactone, and ultraviolet irradiation. Thrombosis and Haemostasis 50:534-536, 1983. [201]

 

Prince AM, Stephan W, Kotitschke R, Brotman B.  Inactivation of the Hutchinson strain non-A, non-B hepatitis virus by combined use of β-propiolactone and ultraviolet irradiation. J Med Virol 16:119-125, 1985. [203]

 

Prince AM, Horowitz B, Dichtelmueller H, Stephan W, Gallo RC. Quantitative assays for evaluation of HTLV-III inactivation procedures: tri (N-butyl) phosphate/sodium cholate and β-propiolactone. Cancer Research 45:4592s-4592s, 1985. [206]

 

Einarsson M, Prince AM, Brotman B.  Removal of non-A, non-B hepatitis-virus from a concentrate of the coagulation factor-II, factor-VII, factor-IX and factor-X by hydrophobic interaction chromatography. Scand J Infec Dis 17:141-146, 1985. [207]

 

Prince AM, Horowitz B, Brotman B.  Inactivation of viruses in labile blood derivatives 3. Sterilization of hepatitis and HTLV-III viruses by exposure to tri (N-Butyl) phosphate and sodium cholate. Lancet i:706-710, 1986. [212]

 

Prince AM. Effect of heat treatment of lyophilized blood derivatives on infectivity of human immunodeficiency virus. Lancet i: 1280, 1986. [215]

 

Prince AM, Horowitz B, Horowitz MS, Zang E.  The development of virus-free labile blood derivatives - a review. Eur J Epidemiol 3:103-118, 1987. [222]

Horowitz B, Piet MPJ, Prince AM, Edwards CA, Lippin A, Walakovits LA.  Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids. Vox Sang 54:14-20, 1988. [237]  


Stephan W, Dichtelmuller H, Prince AM, Brotman B, Huima T.  Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by β-propiolactone. J Med Virol 26:227-232, 1988. [238]

 

Horowitz B, Prince AM.  Laboratory and preclinical evaluation of the virus safety of coagulation factor concentrates. Develop Biol Standard 67:291-302, 1987. [244]

 

Horowitz B, Williams B, Rywkin S, Prince AM, Pascual D, Geacintov N, Valinsky J.  Inactivation of viruses in blood with aluminum phthalocyanine derivatives.  Transfusion 31(2): 102-108, 1991. [263]

   

Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW.  Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood 79:826-831, 1992. [287]

 

Gao F, Prince AM, Pascual D, Horowitz B.  Enhancement in the safety of immune globulins prepared from high-risk plasma. Vox Sang 64:204-209, 1993. [290]

 

Horowitz B, Prince AM, Hamman J, Watklevicz, C.  Viral safety of solvent/detergent treated blood products. Blood Coagulation and Fibrinolysis 5:S21-S28, 1994. [295]

 

Prince AM, Horowitz B.  Virus safety of pooled fresh-frozen plasma inactivated by solvent/detergent treatment. Transfusionsmedizin  31: 21-24, 1993. [304]

 

Lavie G, Mazur Y, Lavie D, Prince AM, Pascual D, Liebes L, Levin B, Meruelo D.  Hypericin as an inactivator of infectious viruses in blood products. Transfusion 35:392-400, 1995. [311]

 

Prince AM, Horowitz B.  Viral safety of solvent/detergent treated intravenous immune globulin. -Letter to the Editor, NEJM 332:1236, 1995. [312]

 

Prince AM, Pascual D, Meruelo D, Liebes L, Mazur Y, Dubovi E, Mandel M, Lavie G. Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin. Photochemistry and Photobiology 71(2): 188-195, 2000. [336]

 

Prince AM.  Hepatitis viruses and blood transfusion. Blood Safety and Surveillance, Linden JV and Bianco C (Eds): Marcel Dekker, Inc., Ch. 12, pp. 279-293, 2001. [338]

 

CHIMPANZEE STUDIES

 

Prince AM.  Infection of chimpanzees with hepatitis B virus. In Vyas, G.N., Perkins, H.A., Schmid R., editors: Hepatitis and Blood Transfusion, New York: Grune & Stratton, pp. 403-406, 1972. [173]

 

Prince AM.  Use of chimpanzees as a model for the study of hepatitis B virus infections. Med Primatol 3:97-109, 1972. [74]

 

Trepo C, Prince AM.  Attempted immunotherapy with dialyzable transfer in hepatitis B carrier chimpanzees: Induction of delayed hypersensitivity to hepatitis B surface antigen (HBsAg).  In Asher, M. (Ed.): Transfer Factor.  New York: Academic Press, pp. 449-456, 1976. [118]

 

Prince AM, Vnek J, Brotman B, Hashimoto N, van den Ende MC.  Comparative evaluations of hepatitis B vaccines in chimpanzees and in man. In Vyas G.N., Cohn S.N, Schmid R. (Eds.): Viral Hepatitis, Philadelphia: Franklin Inst. Press, pp. 507-523, 1978. [138]

 

Prince AM, Brotman B, van den Ende MC, Richardson L.  Non-A, non-B hepatitis: Reproduction of disease in chimpanzees and identification of virus specific antigen and antibody.  In Touraine JL, et al., (Eds.): Transplantation and Clinical Immunology, Amsterdam: Excerpta Medica 10:8-17, 1979. [140]

 

Van den Ende MC, Brotman B, Prince AM.  ÒAn open air holding system for chimpanzees in medical experiments.Ó Develop. Biol. Standard. Basel: S. Karger 45:95-98, 1980. [148]

 

Prince AM.  ÒThe use of chimpanzees in biomedical research.Ó Trends in Bioassay Methodology: In vivo, In vitro and Mathematical Approaches, US Government Printing Office, 1981, pp. 81-97. [160]

 

Prince AM.  Reliability of chimpanzee model for non-A, non-B hepatitis. Lancet ii: 1134, 1985. [208]

 

Prince AM, Brotman B, Hannah A, Donnelly M, Hentschel K, Roth H.  Rehabilitation and release to the wild of chimpanzees used in medical research. SSC/UUCN Primate Specialist Group, 1986. [218]  


Lenz G, Junger H, Schneider M, Kothe N, Lissner R, Prince AM.  Elimination of pyridoxylated polyhemoglobulin after partial exchange transfusion in chimpanzees. Biomat Art Cells & Immob Biotech 19(4): 699-708, 1991. [276]

 

Lenz G, Junger H, van den Ende R, Brotman B, Prince AM.  Hemodynamic effects after partial exchange transfusion with pyridoxylated polyhemoglobin in chimpanzees. Biomat Art Cells & Immob Biotech 19(4): 709-718, 1991. [277]

 

Abe K, InchauspŽ G, Shikata T, Prince AM.  Three different patterns of hepatitis C virus infection in chimpanzees. Hepatology 15:690-695, 1992. [285]

 

Luder CGK, Soboslay PT, Prince AM, Greene BM, Lucius R, Schultz-Key H.  Experimental onchocerciasis in chimpanzees: cellular responses and antigen recognition after immunization and challenge with Onchocerca volvulus infective third-stage larvae. Parasitology 107:87-97, 1993. [302]

 

Prince AM, Whalen R, Taylor P, Brotman B.  Protective efficacy of DNA-based immunization against HBV in newborn chimpanzees. Vaccines 97. Cold Spring Harbor Laboratory 141-144. [322]

 

Prince AM, Whalen R, Brotman B.  Successful nucleic acid based immunization of newborn chimpanzees against hepatitis B virus.  Vaccine 15: 916-919, 1997. [327a]

 

Prince AM, Brotman B.  Biological and immunological aspects of hepatitis C virus infection in chimpanzees.  Curr Stud Hematol Blood Transf 62:250-265, 1998. [324]